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ABSTRACT 
Background 
Multiple cranial nerve blocks of the greater and lesser occipital, supraorbital, supratrochlear 
and auriculotemporal nerves are widely used in the treatment of primary headaches.  We 
present efficacy and safety data for these procedures. 
Methods  
In an uncontrolled open-label prospective study, 119 patients with chronic cluster headache, 
chronic migraine, short lasting unilateral neuralgiform attack disorders, new daily persistent 
headaches, hemicrania continua and chronic paroxysmal hemicrania were examined.   All had 
failed to respond to greater occipital nerve blocks.  Response was defined as a 50% reduction 
in either daily attack frequency or moderate-to-severe headache days after two weeks.   
Results 
The response rate of the whole cohort was 55.4%: chronic cluster headache 69.2%, chronic 
migraine 49.0%, short lasting unilateral neuralgiform attack disorders 56.3%, new daily 
persistent headache 10.0%, hemicrania continua 83.3% and chronic paroxysmal hemicrania 
25.0%.  Time to benefit was between 0.50 and 33.58 hours.  Benefit was maintained for up to 
four weeks in over half responders in all groups except chronic migraine and paroxysmal 
hemicrania.  Only minor adverse events were recorded. 
Conclusion 
Multiple cranial nerve blocks may provide an efficacious, well tolerated and reproducible 
transitional treatment for chronic headache disorders when greater occipital nerve blocks have 
been unsuccessful. 
  
Pg. 3 
 
INTRODUCTION 
Patients with primary headaches often complain of pain involving both the frontal (trigeminal 
innervation) and posterior (occipital nerves innervation) regions.  This is due to the anatomical 
link between cervical and trigeminal afferents onto neurones within the trigeminocervical 
complex (TCC) 1.  Peripheral nerve blocks targeting the occipital or trigeminal nerve branches 
of the scalp used in the treatment of headache are believed to exert effects via the TCC 2.   
Peripheral nerve blocks provide prompt relief for patients with headache disorders.  Their 
benefit has been shown to last beyond the period of local anaesthesia 3, 4.  The common target 
for peripheral nerve blocks is the greater occipital nerve (GON).  However, other nerves 
innervating the scalp including the lesser occipital nerve (LON) and numerous branches of the 
trigeminal nerve such as the supratrochlear (STN), supraorbital (SON), and auriculotemporal 
(ATN) nerves can also be targeted. 
The outcomes of greater occipital nerve blocks (GONB) have been widely produced in open-
label studies in cluster headache 3, 5-8 6, 7 , chronic migraine3, 9 (CM), hemicrania continua (HC)3, 
10-12, short lasting unilateral neuralgiform headache attacks3, 13, 14 and chronic paroxysmal 
hemicrania3, 11 (CPH).  Controlled trials are few but have been performed in cluster headache 
15, 16 and migraine17-20. 
The use of blocks of multiple occipital and trigeminal nerve branches has not been well 
explored.  We wished to explore the efficacy and safety of multiple cranial nerve blocks 
(MCNB) consisting of the GON, LON, SON, STN and ATN in patients with chronic 
headaches. 
 
METHODS 
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Standard protocol approvals, registrations, and patient consents 
This study received ethics approval from the Northwick Park Hospital NHS Research Ethics 
Committee.  All patients provided written consent. 
Patients 
Consecutive patients with chronic headaches receiving MCNB as part of their routine clinical 
care at the National Hospital for Neurology and Neurosurgery, London, between May 2010 
and September 2015 were assessed.  Patients were diagnosed according to the International 
Classification of Headache Disorders (2nd edition)21.  Where multiple phenotypes existed, each 
met the relevant criteria.  All patients with CPH or HC had had documented positive 
indomethacin tests but were unable to continue with indomethacin long term due to side effects 
or medical co-morbidities. Patients were offered MCNB if previous GONB were unsuccessful 
or efficacy faded with repeated injections (Table 1).  
 
Multiple Cranial Nerve Block Procedure 
Injections were undertaken by three headache specialist nurses.  The MCNB protocol involved 
a 50:50 mixture of 1ml lidocaine 2% and 1ml bupivacaine 0.5% for the SON, ATN, STN and 
LON, and 2ml 80mg methylprednisolone, 1ml 2% lidocaine and 1ml 0.5% bupivacaine for the 
GON.  The amount injected was dependent on the procedure being unilateral or bilateral (Table 
2).  Repeated injections were employed on the basis of clinical need and were given a minimum 
of three months apart. 
Figure 1illustrates the injection sites.  Localisation of the nerves was as follows: 
Greater occipital nerve: at a point lying on the medial third of a line drawn between the 
occipital protuberance and mastoid process. 
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Lesser Occipital nerve: at a point lying two-thirds of the way on the line drawn between the 
occipital protuberance and mastoid process 
Supratrochlear nerve: at a point just above the superomedial aspect of the orbit 
Supraorbital nerve: at a point just above the supraorbital notch (mid-pupillary line) 
Auriculotemporal nerve: first injection at a point 1-1.5cm above the root of the helix of ear; 
second injection 1-1.5cm in front of first injection site; third injection 2-3cm above upper tip 
of ear; fourth injection 2-3cm anterior to the third; fifth injection 2-3cm anterior to the fourth.  
If procedure is unilateral then a sixth injection is placed 2-3cm above the fourth. 
The procedure took approximately 10 minutes to complete. As this procedure was offered as 
part of a patient’s routine clinical care, changes in preventative medication were allowed as 
was the use of acute medication. 
The maximum safe dose for infiltration or subcutaneous injections of lidocaine is 4.5mg/kg per 
dose. A 70kg adult can therefore have lidocaine 315mg infiltrated. In this study we infiltrated 
a total lidocaine dose of 220-240mg.The maximum safe dose for infiltration or subcutaneous 
injections of bupivacaine is 175mg per dose. In this study we infiltrated a total bupivacaise 
dose of 40-45mg.22 
 
Data Collection 
Data was collected prospectively using headache diaries and entered onto a clinical database 
(Microsoft Excel, Microsoft Corporation, Redmond, WA, USA.).  Patients kept prospective 
headache diaries for one month before and after MCNB.  Where multiple phenotypes existed, 
patients were asked to keep separate diaries for each pain type.  Average values of all headache 
measures were calculated for the two weeks prior to and after MCNB as well as weeks 3-4.  
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Collected data included patient demographics, headache phenotype, headache days (any day 
on which pain was recorded23), moderate-to-severe headache days (days on which verbal rating 
scale of pain was four or more lasting at least four hours 23), daily attack frequency, average 
daily pain/attack severity, average daily pain/attack duration and adverse events.   
Primary outcome measure was the number of patients responding to treatment.  Response was 
defined as a 50% or more reduction in mean moderate-to-severe headache days (for CM, 
NDPH and HC) or attack frequency (for CCH, SUNCT/SUNA and CPH) over the first two-
weeks.  Secondary outcomes included changes in headache days, pain/attack duration, daily 
pain/attack intensity, pain free days over the first two-weeks and the same measurements after 
weeks three and four.  Total duration of effect and total pain free days were collated as was 
information on repeated procedures.  Information on these longer-term outcomes was obtained 
and recorded during routine follow-up clinics. 
 
Statistics 
Continuous variables are summarized using mean, standard deviation and range, while 
categorical variables were summarized with percentages.  Mean values pre- and post-treatment 
were compared using paired t-tests.  Statistical significance level was set at the 95% level 
(p=0.05).  Data was processed using IBM SPSS Statistics version 22 (IBM Corp. Int.) 
 
RESULTS 
Demographics 
A total of 119 patients receiving initial MCNB were analysed with 137 headache phenotypes 
treated (17 patients documenting multiple phenotypes on separate diaries).  The mean age of 
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the whole group was 48.51 years (±12.13) and 55 patients (46.2%) were male.  Phenotypes 
included CCH (43.7%), CM (41.2%), short lasting unilateral neuralgiform attack disorders 
(13.4%), NDPH with migrainous features (8.4%), HC (5.0%) and CPH (3.4%).  Patients were 
complex and many had failed multiple medications prior to MCNB.  The breakdowns of 
headache diagnosis and demographics are shown in Table 1. 
Efficacy  
The efficacy of response was determined on the basis of the average attack frequency (for 
cluster headache, short lasting unilateral neuralgiform attack disorders and paroxysmal 
hemicrania) or moderate-to-severe headache days over the first two weeks.  Of the 137 
headaches treated, 76 (55.4%) showed a positive response.  The breakdown of response rates 
by phenotype is shown in Figure 2A. 
 
Chronic Cluster headache (see Table 3 and Table 4) 
The responder rate in CCH at two weeks was 69.2% (36/52).  In responders (n=36), mean 
change in daily attack frequency was reduced by 3.33 (95% CI 2.78, 3.89) or 81.8% (±19.93) 
(p<0.001) and the mean number of pain-free days increased by 7.31 days (±5.98) (p<0.001).  
After weeks 3-4, 88.9% (32/36) of responders still exhibited a positive effect.  Mean time to 
response was 22.47 hours (±26.63).  Significant improvements were also seen in attack severity 
and duration. Total reported time of benefit was 57.11 days (±47.70) and total number of 
reported pain-free days post-MCNB was 29.69 days (±48.66).  Mean subjective benefit in 
responders was 69.6% (±30.00).  Results at four weeks are shown in table 4. 
 
Chronic migraine (see Table 3 and Table 4)         
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The response rate in CM at two weeks was 49.0% (24/49).  In responders (n=24), moderate-
to-severe headache days reduced by 10.04 (95% CI 8.61, 11.46) (p<0.001).  Average pain-free 
days over the first two weeks was 4.74 (±5.33) (p<0.001).  Significant improvements were seen 
in the other measures. After the final two weeks, 54.2% (13 patients) were still recording a 
response.  Time to response was 33.58 hours (±41.15), reported duration of benefit was 47.12 
days (±23.69) and total reported pain-free days after the procedure was 6.33 (±9.00).  Mean 
subjective benefit in responders was 59.95% (±35.44).  Results at four weeks are shown in 
table 4. 
 
Short lasting unilateral neuralgiform headache attack disorders (see Table 3 and Table 4) 
Response rate at two weeks in SUNCT/SUNA was 56.3% (9/16).  In responders (n=9), attack 
frequency reduced by 95.7% (±7.36) to 0.33 (±0.50) (p=0.003).  Pain free days were 8.78 
(±6.18) at two weeks compared to zero at baseline (p=0.003).  Significant improvements were 
observed in attack severity (p<0.001) but not duration (p=0.068). At week four, all nine patients 
were still exhibiting response.  Time to benefit was 29.89 hours (±28.22), total reported benefit 
was 68.33 days (±70.22) and total number of pain free days reported was 11.89 (±14.36).  Mean 
estimated improvement in responders was 67.7% (±39.22).  Results at four weeks are shown 
in table 4. 
 
New daily persistent headache with migrainous features (NDPH) (see Table 3 and Table 4) 
In the NDPH group, only one patient from ten (10.0%) showed response after two weeks.  This 
patient reported a 50.0% reduction in moderate-to-severe headache days from 14.00 to 7.00 
but still had daily headaches.  They did not report meaningful change in daily pain duration or 
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severity.  At week four, the patient had returned to baseline.  Time to response was 24.00 hours, 
duration of benefit was 14.00 days and the patient did not report any pain free days post-
MCNB.  Results at four weeks are shown in table 4. 
 
Hemicrania continua (see Table 3 and Table 4) 
Response rate in the HC group was 83.3% (5/6) after two weeks.  Responders (n=5) showed a 
mean reduction of 11.20 (95%CI 6.35, 16.04) moderate-to-severe headache days (p=0.003).  
Mean pain free days after two weeks was 11.00 (±2.82) compared to 0.2 (±0.45) (p=0.001).  
Significant improvements were seen in all other outcome measures.  At week four, 80.0% (n=4) 
still showed a clinical response.  Time to benefit was 24.80 hours (±15.59), duration of benefit 
was 61.80 days (±33.41) and total pain-free days post-procedure was 41.80 days (±45.49).  
Estimated benefit in responders was 96.0% (±8.94).  Results after four weeks are shown in 
table 4. 
 
Chronic paroxysmal hemicrania (see Table 3 and Table 4) 
The response rate in CPH was 25.0% (1/4).  In the single responder, the average daily attack 
frequency reduced to zero and the patient reported nine pain free days.  After week four, the 
patient still showed a positive response. Estimated improvement in responders was 95.0%.  
Time to benefit was 0.50 hours, total duration of benefit was 40.00 days and total number of 
pain free days in this time was 20.00.  Results after four weeks are shown in table 4. 
 
Reproducibility of MCNB response 
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The mean number of procedures undertaken and the response rate of repeated MCNB in each 
headache group is shown in Figure 2B.   Of the 76 patients with an initial response, 45 (56.3%) 
went on to have at least one further MCNB.  The average time between procedures was 6.27 
months (7.42).  The average duration of successful repeated procedures was not significantly 
different from the first MCNB in CCH (52.88 vs 50.54 days, p=0.480), CM (37.82 vs 40.82 
days, p=0.582), SUNCT/SUNA (37.50 vs 37.00, p=0.944) or HC (70.25 vs 52.50, p=0.229).  
Repeated MCNBs were not conducted for any PH or NDPH patients. 
 
Adverse events (see Table 1) 
In the 24-hours post procedure nine patients (7.5%) reported side effects: dizziness in 7 (5.8%), 
blurred vision in 1 (0.8%) and injection site tenderness in 1 (0.8%).  Adverse events were 
reported up to one-month in 17 (14.2%) patients: injection site tenderness 7 (5.8%), transient 
worsening of headaches 3 (2.5%), nausea 3 (2.5%), neck pain 2 (1.6%) and one each of blurred 
vision (0.8%) and numbness over injection sites (0.8%).  All adverse events were transient and 
resolved fully without treatment. 
 
DISCUSSION   
This is the first large series to examine the potential use of MCNB as a transitional treatment 
for chronic headache.  Patients had a protracted history and had failed to benefit from, or had 
reducing efficacy from GONB.  In such a group, the choice of alternative transitional 
treatments is limited.  Oral steroids can be considered in CCH but have potentially serious 
adverse events, intravenous (IV) dihydroergotamine (DHE) may be useful but is increasingly 
difficult to source in the UK and both IV DHE and IV lidocaine require a hospital admission.  
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Multiple cranial nerve blocks appear to offer a valuable and potentially efficacious treatment 
option in such patients.  Of the 137 headaches treated, 55.4% showed a positive response after 
two weeks.  The response rates by phenotype were CCH 69.2%, CM 49.0%, SUNCT/SUNA 
56.3%, NDPH 25.0%, HC 83.3% and CPH 10.0%.  The benefit was maintained at four weeks 
in over half of original responders in CCH, SUNCT and HC.  Significant improvements were 
seen in pain free days, attack frequency, moderate-to-severe headache days, pain duration and 
severity.  Benefit seemed to be sustained for weeks in those that showed response except for 
NDPH where benefit lasted only two weeks in a single patient. 
As this was a study conducted in real life clinical setting, patients could have had concurrent 
changes to their preventative medications whilst receiving a MCNB.  At the time of MCNB, 
60 patients (50.4%) had medication doses changed.  However, we would argue that given that 
there is a considerable delay in the time to effect of preventative medication and that drugs 
being reduced had proved to be ineffective, allowing medication alterations was unlikely to 
have influenced the data collected within four weeks of any medication change.  The MCNB 
are used as a transition treatment, often whilst waiting for a preventative to take effect and we 
therefore think the settings and findings of the study clinically relevant. 
It is difficult to compare our findings to previously published data due to the injection regime 
being so different.  It is even difficult to directly compare studies on GONB in headache as 
although widely used there is no set consensus on injection site, constituents and doses of the 
block, if the steroids should be used, the injection regime (single shot vs. repeated injections 
over a short period), the definitions of response and what headaches to treat 24.  Similarly, it 
seems inappropriate to simply compare GONB response to MCNB response given all our 
patients had failed to show sustained response to routine GONB.  However, as of yet, there is 
no other report on outcomes of multiple cranial nerve block injections given in both greater 
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and lesser occipital and trigeminal nerve territories and so we can only discuss in the context 
of GONB data, which is not ideal as acknowledged above. 
In CCH, our group reported a 57% response to single GONB with median duration benefit of 
21 days 5.  Placebo-controlled trials of GOB in CCH conducted by Ambrosini et al.15 and 
Leroux et al.16 reported 57% of those treated with steroids being pain free at four weeks 
compared to zero with placebo and 86% of cluster headache patients (14 CCH) receiving 
steroid showing a more than 50% reduction in attack frequency after two weeks versus 59% of 
placebo (a non-significant difference), respectively.   
Two placebo-controlled trials on purely CM patients have been conducted to date. One found 
no difference in mean duration of headache-freedom between local anaesthetic (3.7 days) 
versus local anaesthetic and steroid injections (1.0 days) in 37 patients20, yet another found that 
the active group had significantly greater reductions in headache days (around 9 days) 
compared to placebo (around 4 days) after one month19.  Open-label studies of GONB in CM 
recorded response rates of 52% from Weibelt et al.9 and 48% by Afridi et al.3    
For other phenotypes there is very little data and no controlled-trials.  In SUNCT/SUNA, Pareja 
et al. found no responders to multiple nerve blocks13 (including SON, GON, stellate ganglion 
and retrobulbar targets) in seven patients whereas a case study from Porta-Etessam et al. 
described a positive outcome14.  Hemicrania continua responded to GONB in 85% of patients 
in the Afridi et al. cohort3.  In HC cohorts undergoing combinations of GON, LON and SON, 
Guerrero et al. reported all nine patients responding for between two and ten months12.  In a 
study examining the outcome of GON, LON and SON blocks in HC, Antonaci et al. found that 
57% responded to SON blocks but zero to either GON or LON blocks11.  The evidence for 
peripheral nerve blocks in CPH consists of one small open-label series of six patients, none of 
whom responded to either GON, LON or SON blocks11,. 
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Given that our response rates to MCNB in patients already having failed to respond to GONB 
are similar to those quoted for the occipital blocks themselves, this suggests that MCNB have 
an efficacy in a more resistant patient group than that studied in the GONB literature.  It would 
perhaps be a step too far to suggest that they may have greater efficacy than GONB alone in 
nerve block naive patients but it would be interesting to compare the procedures directly to 
ascertain if this is why they still have similar response rates to GONB despite their use in more 
refractory patient groups.  
The issue of the placebo effect in injectable treatments must be considered when assessing the 
effect of MCNB and similar procedures.  Although it is widely assumed that invasive 
treatments have a higher placebo rate than oral medication, the studies in headache on the 
placebo effect of injectable treatments is still lacking.  In the studies mentioned above, different 
injection protocols and the use of lidocaine as a placebo all mean the placebo response to even 
GONB is unknown.  In a meta-analysis of GONB in migraine, pooled results show that in terms 
of pain reduction GONB is significantly better than placebo, suggesting they do have a real 
treatment effect.  However, the use of multiple injections may increase the placebo effect and 
this has to be considered when looking at the efficacy of treatments such as MCNB.  Clinically, 
what is important for the patient, especially in complex and refractory groups, is if patients 
exhibit a useful benefit even if the placebo effect cannot be quantified.  When the procedure 
does appear to be safe and well tolerated, a pragmatic approach should surely be applied to 
help highly disabled patients. 
 
The adverse event profile of GONB in headache patients has been favourable with most cohorts 
reporting only minor adverse events of injection site pain, dizziness and neck pain being most 
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common.   Our cohort found a very similar adverse event profile to those published in GONB 
despite the increase in injection sites.  
It is important that transitional treatments work quickly and that is why we examined the effect 
of MCNB after two weeks.  It is also important that any benefit is sustained, and this study 
shows that this is the case.  Equally essential is a favourable adverse event profile and again, 
our data shows this.  Furthermore, we show a reproducible effect in responders which may 
allow significant periods of relief from chronic headaches in patients failing to respond to 
standard GONB.  As with GONB, the repeated use of MCNB avoids the cost and side effects 
of oral steroids, IV DHE or IV lidocaine. 
In conclusion, our study suggests that MCNB can be rapidly efficacious in chronic headache 
providing reproducible benefit for a number of weeks even in those failing GONB.  Our 
injection protocol appears to offer side effects comparable to GONB.  We suggest that MCNB 
could be a useful addition to the transitional treatments already used for chronic headache. 
 
Clinical implications 
 Peripheral nerve blocks are widely employed in the transitional treatment of a wide 
variety of headache disorders 
 Multiple cranial nerve blocks of the greater and lesser occipital nerves, 
auriculotemporal, supraorbital and supratrochlear nerves can be effective even in 
patients who have failed to respond to greater occipital nerve blocks alone 
 The effects of multiple cranial nerve blocks can be rapid in onset and can last a number 
of weeks 
 Side effects appear to be comparable to greater occipital nerve blocks 
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 CCH (n=52) CM (n=49) SUNCT/SUNA 
(n=16) 
NDPH (n=10) HC (n=6) PH (n=4) 
Sex 
Male 
Female 
 
30 (57.7%) 
22 (42.3%) 
 
21 (42.9%) 
28 (57.1%) 
 
3 (18.8%) 
13 (81.3) 
 
5 (50.0%) 
5 (50.0%) 
 
0 
6 (100%) 
 
3 (75.0%) 
1 (25.0%) 
Age (SD) 
Range 
47.98 (±10.74) 
20-69 
48.84 (±12.60) 
22-79 
45.69 (±12.99) 
21-65 
48.30 (±12.51) 
29-67 
57.33 (±9.56) 
42-67 
50.00 (±12.32) 
34-64 
Number headache types 
1 
2 
3 
 
43 (82.7%) 
8 (15.4%) 
1 (1.9%) 
 
35 (71.4%) 
13 (26.5%) 
1 (2.0%) 
 
7 (43.8%) 
8 (50.0%) 
1 (6.3%) 
 
8 (80.0%) 
2 (20.0%) 
0 
 
5 (83.3%) 
1 (16.7%) 
0 
 
4 (100.0%) 
0 
0 
Co-existent Phenotypes 
Chronic cluster headache 
Chronic migraine 
SUNCT/SUNA 
HC 
 
N/A 
8 (15.4%) 
2 (3.8%) 
0 
 
8 (16.3%) 
N/A 
6 (12.2%) 
1 (2.0%) 
 
1 (6.3%) 
6 (37.5%) 
N/A 
0 
 
0 
0 
2 (20.0%) 
0 
 
0 
1 (16.7%) 
0 
N/A 
 
0 
0 
0 
0 
Pg. 20 
 
NDPH 
PH 
0 
0 
0 
0 
2 (12.5%) 
0 
N/A 
0 
0 
0 
0 
N/A 
Duration chronic headache 
(years) 
8.65 (±6.03) 
1-24 
11.41 (±10.45) 
2-51 
7.38 (±5.13) 
2-19 
17.50 (±7.85) 
9-26 
11.33 (±7.09) 
2-23 
17.50 (±7.85) 
9-26 
Laterality of attacks 
Strictly unilateral 
Unilateral but side variable 
Bilateral 
 
41 (78.8%) 
11 (21.2%) 
0 
 
11 (22.4%) 
11 (22.4%) 
27 (55.1%) 
 
12 (75.0%) 
4 (25.0%) 
0 
 
7 (70.0%) 
0 
3 (30.0%) 
 
5 (83.3%) 
1 (16.7%) 
0 
 
3 (75.0%) 
1 (25.0%) 
0 
Previous medications 8.71 (±3.73) 
0-15 
9.73 (±3.69) 
2-19 
8.00 (±2.21) 
4-12 
9.80 (±2.86) 
6-15 
7.50 (±3.27) 
4-13 
7.75 (±3.77) 
4-11 
Number GONB in past 
 
 
1 
2 
1.75 (±0.98) 
1-4 
 
29 (55.8%) 
11 (21.2%) 
1.94 (±1.77) 
1-12 
 
27 (55.1%) 
12 (24.5%) 
2.31 (±2.21) 
1-8 
 
11 (68.8%) 
3 (18.8%) 
1.80 (±2.20) 
1-8 
 
8 (80.0%) 
1 (10.0%) 
2.33 (±1.75) 
1-5 
 
3 (50.0%) 
1 (16.7%) 
3.00 (±2.82) 
1-7 
 
2 (50.0%) 
0 
Pg. 21 
 
3 
4 
5+ 
8 (15.4%) 
4 (7.7%) 
0 
4 (8.2%) 
5 (10.2%) 
1 (2.0%) 
0 
0 
2 (12.6%) 
0 
0 
1 (10.0%) 
0 
1 (16.7%) 
1 (16.7%) 
1 (25.0%) 
0 
1 (25.0%) 
Response to first GONB 
No response 
Response (more than 50% 
least 14 days) 
Partial response 
Worsening 
 
18 (34.6%) 
8 (15.4%) 
 
21 (40.4%) 
5 (9.6%) 
 
22 (44.9%) 
6 (12.2%) 
 
17 (34.7%) 
4 (8.2%) 
 
8 (50.0%) 
0 
 
3 (18.8%) 
3 (18.8%) 
 
9 (90.0%) 
0 
 
1 (10.0%) 
0 
 
2 (33.3%) 
1 (16.7%) 
 
1 (16.7%) 
2 (33.3%) 
 
1 (25.0%) 
1 (25.0%) 
 
0 
2 (50.0%) 
Injection Site 
Unilateral 
Bilateral 
 
43 (82.7%) 
9 (17.3%) 
 
14 (28.6%) 
35 (71.4%) 
 
8 (50.0%) 
8 (50.0%) 
 
6 (60.0%) 
4 (40.0%) 
 
4 (66.7%) 
2 (33.3%) 
 
4 (100.0%) 
0 
Immediate side effects 
Dizziness 
Blurred vision 
Injection site tenderness 
9 (17.3%) 
7 (13.5%) 
1 (1.9%) 
1 (1.9%) 
9 (18.3%) 
5 (10.2%) 
1 (2.0%) 
2 (4.1%) 
2 (12.6%) 
1 (6.3%) 
0 
0 
2 (20.0%) 
1 (10.0%) 
0 
1 (10.0%) 
1 (16.7%) 
1 (16.7%) 
0 
0 
0 (0.0%) 
Pg. 22 
 
Worsening/triggering 
headache 
0 1 (2.0%) 
 
1 (6.3%) 0 
 
0 
 
Adverse Events 
Neck pain 
Injection site tenderness 
Numbness over injection 
sites 
Worsening headaches 
Blurred vision 
Nausea 
Dizziness 
17 (32.7%) 
2 (3.8%) 
7 (13.5%) 
1 (1.9%) 
 
3 (5.8%) 
1 (1.9%) 
3 (5.8%) 
0 
13 (26.4%) 
1 (2.0%) 
6 (12.2%) 
0 
 
4 (8.2%) 
0 
1 (2.0%) 
1 (2.0%) 
4 (25.0%) 
0 
1 (6.3%) 
0 
 
1 (6.3%) 
0 
0 
2 (12.6%) 
6 (60.0%) 
1 (10.0%) 
2 (20.0%) 
0 
 
4 (40.0%) 
0 
0 
0 
1 (16.7%) 
0 
0 
0 
 
0 
0 
0 
1 (16.7%) 
2 (50.0%) 
0 
1 (25.0%) 
0 
 
1 (25.0%) 
0 
0 
0 
 
CCH, chronic cluster headache; CM, chronic migraine; GONB, greater occipital nerve; HC, hemicrania continua; NDPH, New Daily Persistent Headache; 
PH, paroxysmal hemicrania; SUNCT, short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA short lasting 
unilateral neuralgiform headache attacks with autonomic features 
 
Table 1: Demographic details by headache phenotype 
  
Pg. 23 
 
 
 Unilateral  
Procedure 
Bilateral  
Procedure 
Supraorbital nerve* 2ml 1ml each side 
Supratrochlear nerve* 2ml 1ml each side 
Auriculotemporal nerve: proximal* § 4ml 2ml each side 
Auriculotemporal nerve: distal* §§ 8ml 3ml each side 
Greater Occipital nerve** 4ml 4ml each side 
Lesser Occipital nerve* 2ml 1ml each side 
 
*50:50 mixture of lidocaine 2% and bupivacaine 0.5% 
** 80mg (2ml) methylprednisolone, lidocaine 2% (1ml), bupivacaine 0.5% (1ml) 
§ proximal auriculotemporal nerve injections are the ones performed just above the root of the 
helix of the ear 
§§ distal auriculotemporal injections are the ones performed superiorly to the level of the 
proximal ones 
 
Table 2: Multiple cranial nerve block injection protocol 
 
 
 
 
 
 
 
 
 
Pg. 24 
 
 
 
 
 Pre 
MCNB 
Post 
MCNB 
Mean change 
(95%CI) 
p-value 
CCH (N=36)     
Total headache days 13.89 
(±0.66) 
6.31 
(±6.11) 
7.58 (5.49, 9.67) <0.001* 
Pain Free days 0.11 
(±0.66) 
7.42 
(±5.98) 
-7.31 (-9.36, -
5.24) 
<0.001* 
Attack frequency 4.17 
(±1.94) 
0.83 
(±1.02) 
3.33 (2.78, 3.89) <0.001* 
Attack duration 1.21 
(±0.96) 
0.40 
(±0.55) 
0.81 (0.44, 1.16) <0.001* 
Attack severity (VRS) 7.69 
(±1.75) 
2.39 
(±2.85) 
5.31 (4.24, 6.36) <0.001* 
CM (N=24)     
Total headache days 13.63 
(±1.05) 
9.13 
(±5.24) 
4.50 (2.45, 6.55) <0.001* 
Pain Free days 0.26 
(±0.91) 
4.74 
(±5.33) 
-4.48 (-6.60, -
2.34) 
<0.001* 
Pg. 25 
 
Moderate-to-severe 
headache days 
12.42 
(±2.91) 
2.38 
(±2.63) 
10.04 (8.61, 
11.46) 
<0.001* 
Daily duration 16.95 
(±3.61) 
8.95 
(±6.96) 
8.00 (5.11, 
10.88) 
<0.001* 
Daily severity (VRS)* 6.25 
(±1.48) 
2.13 
(±1.51) 
4.12 (3.29, 4.95) <0.001* 
Moderate-to-severe 
headache days 
12.42 
(±2.91) 
6.04 
(±4.85) 
6.38 (4.25, 8.49) <0.001* 
Daily duration 16.95 
(±3.61) 
10.66 
(±5.96) 
6.29 (3.62, 8.96) <0.001* 
SUNCT/SUNA (N=9)     
Total headache days 14.00 
(±0.00) 
5.00 
(±6.36) 
9.00 (4.10, 
13.89) 
0.003* 
Pain free days 0.00 8.78 
(±6.18) 
-8.78 (-13.52, -
4.02) 
0.003* 
Attack frequency 30.22 
(±28.78) 
0.33 
(±0.50) 
29.89 (7.57, 
52.19) 
0.015* 
Attack duration 0.12 
(±0.18) 
0.01 
(±0.05) 
0.10 (-0.01, 
0.21) 
0.068 
Attack severity (VRS)* 9.33 
(±0.86) 
2.00 
(±3.50) 
7.33 (4.81, 9.85) <0.001* 
Pg. 26 
 
NDPH (n=1)     
Total headache days 14.00 14.00 N/A N/A 
Pain free days 0.00 0.00 N/A N/A 
Moderate-to-severe days 14.00 7.00 N/A N/A 
Attack duration 15.00 15.00 N/A N/A 
Daily severity (VRS)* 5.00 4.00 N/A N/A 
HC (n=5)     
Total headache days 13.83 
(±0.44) 
 
2.40 
(±3.36) 
11.40 (6.95, 
15.84) 
0.002* 
Pain Free days 0.20 
(±0.45) 
11.00 
(±2.82) 
-10.80 (-14.57, -
7.03) 
0.001* 
Moderate-to-severe 
headache days 
11.20 
(±3.89) 
0.00 
(±0.00) 
11.20 (6.35, 
16.04) 
0.003* 
Daily duration 14.40 
(±3.64) 
1.00 
(±2.23) 
13.40 (9.61, 
17.18) 
0.001* 
Daily severity (VRS)* 6.40 
(±1.81) 
0.20 
(±0.45) 
6.20 (4.16, 8.24) 0.001* 
PH (n=1)     
Pg. 27 
 
Total headache days 14.00 5.00 N/A N/A 
Pain Free days 0 9 N/A N/A 
Attack Frequency 4.00 0.00 N/A N/A 
Daily duration 0.30 0.12 N/A N/A 
Daily severity (VRS)* 8.00 1.00 N/A N/A 
 
CCH, chronic cluster headache; CI, confidence interval; CM, chronic migraine; HC, hemicrania 
continua; MCNB, Multiple cranial nerve block; N/A, data not available due to single responder; 
NDPH, New Daily Persistent Headache; PH, paroxysmal hemicrania; SUNCT, short lasting unilateral 
neuralgiform headache attacks with conjunctival injection and tearing; SUNA short lasting unilateral 
neuralgiform headache attacks with autonomic features; VRS, verbal response scale 
 
Table 3: Outcome at two weeks for all headache types 
 
 
  
Pg. 28 
 
RESPONDERS Pre MCNB Post 
MCNB 
Mean change 
(95%CI) 
p-
value 
CCH (N=36)     
Response rate after 4 (in those 
responding at 2 weeks) 
88.9 
Total headache days 13.89 
(±0.66) 
6.67 
(±6.01) 
7.22 (5.12, 
9.31) 
<0.001 
Pain Free days 0.11 
(±0.66) 
7.33 
(±6.01) 
-7.22 (-9.31, -
5.12) 
<0.001 
Attack frequency 4.17 
(±1.94) 
1.11 
(±1.11) 
3.06 (2.47, 
3.63) 
<0.001 
Attack duration 1.21 
(±0.96) 
0.42 
(±0.58) 
0.79(0.49, 1.08) <0.001 
Attack severity (VRS) 7.69 
(±1.75) 
3.03 
(±2.97) 
4.67 (3.58, 
5.76) 
<0.001 
CM (N=24)     
Response rate after 4 (in those 
responding at 2 weeks) 
50.0% 
Total headache days 13.63 
(±1.05) 
10.88 
(±4.89) 
2.75 (0.89, 
4.60) 
0.005 
Pg. 29 
 
Pain Free days 0.26 
(±0.91) 
3.13 
(±4.89) 
-2.75 (-4.60, -
0.89) 
0.005 
Moderate-to-severe headache days 12.42 
(±2.91) 
6.04 
(±4.85) 
6.38 (4.25, 
8.49) 
<0.001 
Daily duration 16.95 
(±3.61) 
10.66 
(±5.96) 
6.29 (3.62, 
8.96) 
<0.001 
Daily severity (VRS)* 6.25 
(±1.48) 
3.33 
(±2.25) 
2.92 (1.86, 
3.97) 
<0.001 
SUNCT/SUNA (N=9)     
Response rate after 4 (in those 
responding at 2 weeks) 
100.0% 
Total headache days 14.00 
(±0.00) 
8.44 
(±6.71) 
5.56 (0.39, 
10.71) 
0.038 
Pain free days 0.00 6.36 
(±2.12) 
-9.00 (-13.89, -
4.10) 
0.003 
Attack frequency 30.22 
(±28.78) 
4.56 
(±5.38) 
25.67 (3.75, 
47.58) 
0.027 
Attack duration 0.12 
(±0.18) 
0.02 
(±0.32) 
0.10 (-0.21, 
0.22) 
0.094 
Attack severity (VRS)* 9.33 
(±0.86) 
3.89 
(±3.72) 
5.44 (2.92, 
7.96) 
0.001 
Pg. 30 
 
NDPH (n=1)     
Response rate after 4 week  (in those 
responding at 2 weeks) 
100.0% 
Total headache days 14.00 14.00 N/A N/A 
Pain free days 0.00 0.00 N/A N/A 
Moderate-to-severe headache days 14.00 14.00 N/A N/A 
Daily duration 15.00 16.00 N/A N/A 
Daily severity (VRS)* 5.00 5.00 N/A N/A 
HC (n=5)     
Response rate after 4 week  (in those 
responding at 2 weeks) 
80.0% 
Total headache days 13.83 
(±0.44) 
 
5.20 
(±7.15) 
8.60 (-0.67, 
17.87) 
0.062 
Pain Free days 0.20 
(±0.45) 
8.80 
(±7.15) 
-8.60 (-17.87, 
0.67) 
0.062 
Moderate-to-severe headache days 11.20 
(±3.89) 
1.80 
(±4.02) 
9.40 (0.20, 
18.59) 
0.047 
Pg. 31 
 
Daily duration 14.40 
(±3.64) 
4.40 
(±6.38) 
10.00 (-2.13, 
22.13) 
0.084 
Daily severity (VRS)* 6.40 
(±1.81) 
1.20 
(±1.64) 
5.20 (0.95, 
9.45) 
0.027 
PH (n=1)     
Response rate after 4 week  (in those 
responding at 2 weeks) 
0.0% 
Total headache days 14.00 1.00 N/A N/A 
Pain Free days 0 13.00 N/A N/A 
Attack Frequency 4.00 0.00 N/A N/A 
Daily duration 0.30 0.00 N/A N/A 
Daily severity (VRS)* 8.00 0.00 N/A N/A 
 
CCH, chronic cluster headache; CI, confidence interval; CM, chronic migraine; HC, hemicrania 
continua; MCNB, Multiple cranial nerve block; N/A, data not available due to single responder; 
NDPH, New Daily Persistent Headache; PH, paroxysmal hemicrania; SUNCT, short lasting unilateral 
neuralgiform headache attacks with conjunctival injection and tearing; SUNA short lasting unilateral 
neuralgiform headache attacks with autonomic features; VRS, verbal response scale 
Table 4: Outcomes after four weeks for all headache types 
  
Pg. 32 
 
Figure 1: Sites of peripheral nerve blocks 
 
  
Pg. 33 
 
Figure 2A and 2B: Response rates of MCNB by headache phenotypes 
 
 
 
CCH, chronic cluster headache; CM, chronic migraine; GONB, greater occipital nerve; HC, 
hemicrania continua; MCNB, multiple cranial nerve block; NDPH, New Daily Persistent Headache; 
PH, paroxysmal hemicrania; SUNCT, short lasting unilateral neuralgiform headache attacks with 
conjunctival injection and tearing; SUNA short lasting unilateral neuralgiform headache attacks with 
autonomic features 
Figure 2A: Response rates after first MCNB by headache phenotype 
 
 
 
 
 
 
 
Figure 2a 
Pg. 34 
 
 
 
 
CCH, chronic cluster headache; CM, chronic migraine; GONB, greater occipital nerve; HC, 
hemicrania continua; MCNB, multiple cranial nerve block; NDPH, New Daily Persistent Headache; 
PH, paroxysmal hemicrania; SUNCT, short lasting unilateral neuralgiform headache attacks with 
conjunctival injection and tearing; SUNA short lasting unilateral neuralgiform headache attacks with 
autonomic features 
Figure 2B: Response rates of repeated MCNB by headache phenotype 
 
Legend Figure 2B 
The average number of MCNB per phenotype was as follows: CCH 2.44 blocks (range 1-8); CM 2.67 
blocks (range 1-8); SUNCT/SUNA 3.56 blocks (range 1-8); NDPH 1 block; PH 1 block.  The number 
of patients undergoing repeated blocks was as follows: CCH 27; CM 17; SUNCT/SUNA 9; NDPH 0; 
HC 4; PH 0. 
 
 
 
Figure 2b 
